Sientra (SIEN) Upgraded to “Hold” at ValuEngine

Sientra (NASDAQ:SIEN) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

A number of other equities research analysts have also commented on the stock. Stifel Nicolaus raised shares of Sientra from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research note on Friday, January 19th. BidaskClub lowered shares of Sientra from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Canaccord Genuity reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Sientra in a research note on Friday, January 5th. Finally, Zacks Investment Research raised shares of Sientra from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. Sientra has an average rating of “Buy” and an average target price of $15.00.

Sientra (NASDAQ SIEN) traded down $0.11 during trading hours on Friday, hitting $11.68. 412,573 shares of the stock were exchanged, compared to its average volume of 406,530. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.92 and a current ratio of 2.87. Sientra has a 12 month low of $7.20 and a 12 month high of $16.68.

Sientra (NASDAQ:SIEN) last posted its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported ($0.74) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.06). Sientra had a negative net margin of 169.77% and a negative return on equity of 68.82%. The firm had revenue of $9.80 million during the quarter, compared to the consensus estimate of $10.54 million. During the same period in the prior year, the company posted ($0.55) earnings per share. The company’s revenue for the quarter was up 50.8% compared to the same quarter last year. equities research analysts forecast that Sientra will post -3.25 earnings per share for the current year.

Several institutional investors have recently added to or reduced their stakes in SIEN. Schwab Charles Investment Management Inc. acquired a new position in shares of Sientra during the 2nd quarter valued at $252,000. Rhumbline Advisers acquired a new position in shares of Sientra during the 2nd quarter valued at $158,000. Bank of New York Mellon Corp lifted its position in shares of Sientra by 74.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 90,274 shares of the medical instruments supplier’s stock valued at $877,000 after acquiring an additional 38,514 shares during the period. JPMorgan Chase & Co. acquired a new position in shares of Sientra during the 2nd quarter valued at $101,000. Finally, Teachers Advisors LLC acquired a new position in shares of Sientra during the 2nd quarter valued at $247,000. Institutional investors own 76.72% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Sientra (SIEN) Upgraded to “Hold” at ValuEngine” was first published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2018/02/04/sientra-sien-upgraded-to-hold-at-valuengine.html.

Sientra Company Profile

Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply